Curi Bio Secures $10M Series B to Scale Human-Relevant Preclinical Platforms and Advanced Data Analysis for Drug Discovery
Saved in:
| Title: | Curi Bio Secures $10M Series B to Scale Human-Relevant Preclinical Platforms and Advanced Data Analysis for Drug Discovery |
|---|---|
| Authors: | Curi Bio |
| Source: | Business Wire (English). 12/02/2025. |
| Abstract: | Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio's human-relevant platforms into global clinical success. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio's human-relevant platforms into global clinical success. [ABSTRACT FROM PUBLISHER] |
|---|
